Merck and Daiichi Sankyo Trial of Ifinatamab Deruxtecan in Advanced Esophageal Cancer
A clinical trial is underway to evaluate ifinatamab deruxtecan (I-DXd) for treating advanced esophageal squamous cell carcinoma.
Asset / Drug
Drug and asset intelligence for Ifinatamab Deruxtecan with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.